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A B S T R A C T
Purpose
Findings on the association between risk of cardiovascular disease (CVD) and the duration and
type of androgen-deprivation therapy (ADT) in men with prostate cancer (PCa) are inconsistent.
Methods
By using data on filled drug prescriptions in Swedish national health care registers, we investigated
the risk of CVD in a cohort of 41,362 men with PCa on ADT compared with an age-matched,
PCa-free comparison cohort (n  187,785) by use of multivariable Cox proportional hazards
regression models.
Results
From 2006 to 2012, 10,656 men were on antiandrogens (AA), 26,959 were on gonadotropin-
releasing hormone (GnRH) agonists, and 3,747 underwent surgical orchiectomy. CVD risk was
increased in men on GnRH agonists compared with the comparison cohort (hazard ratio [HR] of
incident CVD, 1.21; 95% CI, 1.18 to 1.25; and orchiectomy: HR, 1.16; 95% CI, 1.08 to 1.25). Men
with PCa on AA were at decreased risk (HR of incident CVD, 0.87; 95% CI, 0.82 to 0.91). CVD risk
was highest during the first 6 months of ADT in men who experienced two or more cardiovascular
events before therapy, with an HR of CVD during the first 6 months of GnRH agonist therapy of
1.91 (95% CI, 1.66 to 2.20), an HR of CVD with AA of 1.60 (95% CI, 1.24 to 2.06), and an HR of
CVD with orchiectomy of 1.79 (95% CI, 1.16 to 2.76) versus the comparison cohort.
Conclusion
Our results support that there should be a solid indication for ADT in men with PCa so that benefit
outweighs potential harm; this is of particular importance among men with a recent history of CVD.
J Clin Oncol 33:1243-1251. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Androgen-deprivation therapy (ADT) is the first
line of treatment for disseminated prostate cancer
(PCa) and is also used as neoadjuvant and adjuvant
therapy in conjunctionwith radiotherapy for locally
advanced PCa.1-3 Alongside its therapeutic bene-
fits, ADT increases the risk of various metabolic ab-
errations including decreased insulin sensitivity,
changes in lipid profiles, and an increased risk of
cardiovascular disease (CVD).4,5 The increased risk
ofCVDinmenwithPCaonADThasbeenobserved
in a number of observational studies,6-17 and one
proposed explanation of this relationship is that
ADT interfereswith the cardioprotective property
of testosterone, thereby increasing the risk for
adverse events.14-16,18
In a previous study, we compared 76,000 men
with PCa to the general Swedish male population
and showed an increased risk of incident and fatal
CVD among all men with PCa.16 The highest rela-
tive risk was observed for those on ADT (eg, stan-
dardized incidence ratio for ischemic heart disease,
1.32; 95% CI, 1.27 to 1.36).16 Together with six
other studies, these data were used by the US Food
and Drug Administration to require a risk label on
gonadotropin-releasing hormone (GnRH) agonists
for increased risk of diabetes and certain CVDs
(heart attack, sudden cardiac death, and stroke).19
Nonetheless, there is considerable disagree-
ment on the association between ADT and CVD in
observational studies versus randomized clinical tri-
als (Fig 1).6-17,20-24 Some of the limiting factors have
been lack of data on different types and duration of
ADT, comparison to patients with PCa not treated
with ADT rather than age-matched, PCa-free men,
and not taking into account pre-existing CVD.
Thus, to further elucidate the impact of ADT and its
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timing on the risk of CVD, we expanded our previous study
cohort in the Prostate Cancer Database Sweden (PCBaSe) by
extending follow-up time and adding a series of PCa-free com-
parison men and data on filled prescriptions from the National
Prescribed Drug Register.
METHODS
Study Population and Data Collection
PCBaSe Sweden 2.0 is based on the National Prostate Cancer Register
(NPCR) of Sweden, which became nationwide in 1998 and covers 98% of all
newly diagnosed, biopsy-confirmed PCas, as compared with the Swedish
Cancer Registry.25 NPCR includes information on date of diagnosis, age at
diagnosis, tumor stage and differentiation, serum levels of prostate-specific
antigen (PSA) at time of diagnosis, and primary treatment within 6 months
after date of diagnosis.25 By use of the Swedish 10-digit personal identity
number, five PCa-free men from the general population in Sweden were
randomly selected within sets of men who matched the index patient on age
( 1 year) and county of residence from the PCBaSe cohort. Patients and the
comparison cohort in PCBaSewere subsequently linked to a series of national
health care registers and demographic databases to obtain data on discharge
diagnoses, surgical procedures, socioeconomic status, and cause of death to be
included in the PCBaSe database.25 Comorbidities were measured by the
Charlson comorbidity index (CCI), which assigns weights to a number of
medical conditions, including diabetes and hypertension, allowing for a final
comorbidity score to be calculated for each individual.26 Each condition is
assigned a score of 1, 2, 3, or 6, and the final CCI score is given as the sum of
these scores. Individuals are grouped intoCCIcategories forfinal scoresof 0, 1,
2, or 3. Information on filled prescriptions of antiandrogens (AA) and
GnRHagonists, includingdate of initiation, duration, anddaily drugdosewas
obtained from the National Prescribed Drug Register.27 The Research Ethics
Board at Umeå University (Umeå, Sweden) approved this study.
Information in PCBaSe on age, serumPSA, treatment at time of diagno-
sis, tumor grade and stage, educational level, history ofCVD(primarydiagno-
ses), and cause and date of death was used. PCa risk category was defined
according to amodification of the National Comprehensive Cancer Network
guidelines,28 as follows: low risk: T1-2, Gleason score of 2 to 6, and PSA less
than10ng/mL; intermediate risk:T1-2,Gleasonscoreof7, and/orPSAof10 to
20 ng/mL; high risk: T3 and/orGleason score of 8 to 10 and/or PSAof 20 to 50
ng/mL; regionallymetastatic/locally advanced:T4and/orN1and/orPSAof50
to 100 ng/mL in the absence of distant metastases (M0 or MX); distant
metastases: M1 and/or PSAmore than 100 ng/mL.25 For the current analysis,
we selectedmenwith PCawho receivedADTas primary treatment or because
of disease progression. Using information from the Patient Register and the
National Prescribed Drug Register, ADTwas grouped into AAmonotherapy;
GnRH agonist monotherapy, includingmen receiving short-term AA as flare
protection or long-term AA ( 6 months) for combined androgen blockade
(CAB); andsurgical orchiectomy.Weperformeda sensitivity analysiswhereby
we excluded men receiving CAB from the GnRH group and saw negligible
differences in risk of CVD; the results remained unchanged or changed in the
second decimal, and thus, those on CAB therapy were included in the GnRH
group for all analyses (Appendix Table A1, online only).
Analysis
Analysiswasperformedon the associationbetweenexposure todifferent
types of ADT and incident and fatal overall CVD (International Classification
of Diseases, Tenth Revision [ICD-10]: I00 through I99) and subtypes thereof,
including ischemicheartdisease (ICD-10: I20 through I25), arrhythmia (ICD-
10: I44 through I49), heart failure (ICD-10: I50), and stroke (ICD-10: I60
through I64, G45). Because PCBaSe has detailed follow-up on five age- and
county-matched PCa-free men for every patient with PCa, we conducted a
prospective cohort study whereby men with PCa on ADT and PCa-free men
Hu et al
Azoulay et al
Jespersen et al
Keating et al (SEER)
Keating et al 
Martin to Merino et al
Van Hemelrijck et al 
Van Hemelrijck et al 
D'Amico et al
Messing et al
Bolla et al
Schröder et al
Studer et al
Efstathiou et al
Roach et al
Denham et al
Relative Risk (95% CI)
RCT*
Observational
study†
0.79 (0.48 to 1.31)
1.23 (0.76 to 2.01)
0.78 (0.56 to 1.10)
0.91 (0.70 to 1.18)
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1.30 (0.71 to 2.38)
3.26 (0.35 to 30.2)
1.02 (0.50 to 2.09)
1.29 (1.07 to 1.56)
0 1 2 3 4
2.38 (2.12 to 2.66)
1.34 (0.99 to 1.82)
1.69 (1.37 to 2.09)
1.64 (1.51 to 1.77)
1.24 (1.08 to 1.42)
1.28 (1.03 to 1.58)
1.39 (1.07 to 1.81)
Fig 1. Relative risks of cardiovascular
disease in men with prostate cancer on
androgen-deprivation therapy in published
randomized clinical trials (RCTs) versus
observational studies. (*) Adopted from
Nguyen et al.24 (†) Adopted from Bosco
et al (manuscript under review).
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wereobserved to identifyoccurrenceofCVD.Hazardratios (HRs) for incident
and fatalCVDwerecalculated formenwithPCaversus thecomparisoncohort
with left truncation using a Cox proportional hazards regression model with
age as a timescale, accounting for tumor risk category, CCI, civil status, edu-
cational level, and baseline history of CVD (ICD-10: I00 to I99).25 Left trun-
cation was applied because the National Prescribed Drug Register started on
July 1, 2005, and we allowed for a run-in period of 6 months. Because of its
linkage with the National Prescribed Drug Register, PCBaSe provides infor-
mation on both primary (recorded in the NPCR and the National Prescribed
Drug Register) and secondary therapy (registered in the National Prescribed
Drug Register only).25 Furthermore, the National Prescribed Drug Register
enables an accurate calculation of the start date of ADT. The association
between duration of ADT and first CVD event, incident or fatal, was assessed
using multivariable Cox proportional hazards models with left truncation,
whereby follow-up time was divided into the following intervals: less than 6
months, 6 to18months, 18 to36months, andmore than36months since start
of ADT. We also compared the number of nonfatal CVD events before and
after initiation ofADT for bothmenwithPCa andPCa-freemen. These crude
comparisons are represented as risk ratios.13 Finally, we also adjusted for PCa
disease progression by using the following proxy variables as time-dependent
covariates: transurethral resection of the prostate (TURP) indicating sub-
vescial obstruction, palliative radiotherapy indicating pain from bone metas-
tases, and use of nephrostomy indicating overgrowth on the ureter. We
included these proxies of disease progression as covariates in the Cox propor-
tional hazards model because we observed an increased risk of incident CVD
for men with PCa who had one of these indications of disease progression
versus men with PCa who did not (HR for CVD for TURP v no TURP, 1.11;
95% CI, 1.03 to 1.20; HR for CVD for palliative radiotherapy v no radiother-
apy, 1.25; 95% CI, 1.17 to 1.35; HR for CVD for nephrostomy v no nephros-
tomy, 1.64; 95%CI, 1.38 to 1.95; Table 1).
All data management was performed using SAS version 9.3 (SAS Insti-
tute, Cary, NC). All data analysis was conducted with R version 2.13.2 (R
Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Of the 41,362 men with PCa, 10,656 were on AAs, 7,789 were on
GnRH agonists, 18,166 were onGnRH agonists with flare protection,
1,004wereonCAB, and3,747underwent surgical orchiectomy(Table
2).Table3 lists theHRs foroverall incident and fatalCVDfordifferent
types of ADT compared with the comparison cohort. There was an
increased risk of incident CVD formen onGnRHagonists (HR, 1.21;
95% CI, 1.18 to 1.25) and who underwent orchiectomy (HR, 1.16;
95%CI, 1.08 to 1.25) comparedwith the comparison cohort.Men on
AAwere at lower risk for CVD (HR, 0.87; 95%CI, 0.82 to 0.91).
To further disentangle the association between ADT and CVD,
we performed an analysis for men with PCa who received ADT as
primary treatment (Table 3). The HRs for incident and fatal CVD in
men treatedwithGnRHagonists or orchiectomy remained similar, as
in the analysis of the full study group. The HR of incident CVD was
1.19 (95%CI, 1.15 to 1.23) formen onGnRHagonists and 1.12 (95%
CI, 1.04 to 1.21) formenwhounderwent orchiectomy.HRs in theAA
groupweremarginally increased for incident and fatal CVD but were
not statistically significant (HR for incident CVD, 0.89; 95% CI, 0.83
to 0.95) compared with the comparison cohort.
To account for additional CVD risk factors, we next ran an
analysis for all men with PCa without a baseline history of CVD and
men with a history of statin use before PCa diagnosis (Table 3). Men
withnohistoryofCVDreceivingGnRHagonistswere still at increased
risk of incident and fatal CVD. The HR for incident CVD was 1.19
(95% CI, 1.14 to 1.24). Men who underwent surgical orchiectomy
were also at an increased risk for CVD (HR for incident CVD, 1.13;
Table 1. Event Counts and HRs for Men With Prostate Cancer Who Did and Did Not Undergo TURP, Palliative RT, and Nephrostomy
Procedure No. of Events No. of Men Exposed
Crude Multivariable
HR 95% CI HR 95% CI
TURP
Incident CVD
No 8,558 38,140 1.00 Reference 1.00 Reference
Yes 679 3,979 1.11 1.03 to 1.20 1.14 1.05 to 1.23
Fatal CVD
No 3,958 40,258 1.00 Reference 1.00 Reference
Yes 369 4,870 1.15 1.04 to 1.28 1.14 1.03 to 1.27
Palliative RT
Incident CVD
No 8,446 38,504 1.00 Reference 1.00 Reference
Yes 791 6,519 1.25 1.17 to 1.35 1.35 1.25 to 1.46
Fatal CVD
No 4,087 40,773 1.00 Reference 1.00 Reference
Yes 240 7,455 1.04 0.92 to 1.19 1.17 1.02 to 1.34
Nephrostomy
Incident CVD
No 9,102 38,922 1.00 Reference 1.00 Reference
Yes 135 1,276 1.64 1.38 to 1.95 1.47 1.24 to 1.74
Fatal CVD
No 4,237 41,257 1.00 Reference 1.00 Reference
Yes 90 1,661 2.19 1.78 to 2.70 1.93 1.56 to 2.38
Abbreviations: CVD, cardiovascular disease; HR, hazard ratio; RT, radiotherapy; TURP, transurethral resection of the prostate.
Adjusted for type of androgen-deprivation therapy, tumor risk category, Charlson comorbidity index, civil status, educational level, and baseline history of CVD
(International Classification of Diseases, Tenth Revision: I00 through I99) using age as a timescale.
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Table 2. Baseline Demographics and Clinical Characteristics of Patients With PCa on ADT and the Matched Comparison Cohort in PCBaSe Sweden 3.0
Demographic or Clinical
Characteristic
Comparison
Cohort
(n  187,785)
Patients With
PCa
(n  41,362)
Patients on
Antiandrogens
(n  10,656)
Patients on
GnRH
Agonists
(n  7,789)
Patients on
GnRH
Agonists With
Flare
Protection
(n  18,166)
Patients on
Combined
Androgen
Blockade
(n  1,004)
Patients With
Surgical
Orchiectomy
(n  3,747)
No. % No. % No. % No. % No. % No. % No. %
Follow-up time, years
Mean 4.4 4.0 3.5 5.3 3.8 3.3 4.3
SD 3.2 3.1 2.6 3.5 3.0 2.6 3.4
Age, years
Mean 75.3 75.7 73.7 75.8 76.4 70.4 78.6
SD 8.1 8.0 7.6 7.8 8.0 9.5 7.2
 65 19,533 10.4 3,997 9.7 1,308 12.3 683 8.8 1,556 8.6 283 28.2 167 4.5
65-74 59,847 31.9 12,774 30.9 4,121 38.7 2,424 31.1 5,108 28.1 377 37.5 744 19.9
75-84 86,039 45.8 19,328 46.7 4,539 42.6 3,701 47.5 8,732 48.1 272 27.1 2,084 55.6
85 22,366 11.9 5,263 12.7 688 6.5 981 12.6 2,770 15.2 72 7.2 752 20.1
Year of PCa diagnosis
1997-2001 19,979 10.6 6,020 14.6 1,215 11.4 1,958 25.1 2,127 11.7 77 7.7 643 17.2
2002-2005 54,757 29.2 12,420 30.0 2,837 26.6 2,988 38.4 5,154 28.4 199 19.8 1,242 33.1
2006-2009 73,117 38.9 14,908 36.0 4,178 39.2 2,074 26.6 6,867 37.8 478 47.6 1,311 35.0
2010-2012 39,932 21.3 8,014 19.4 2,426 22.8 769 9.9 4,018 22.1 250 24.9 551 14.7
Charlson comorbidity index at
onset of ADT
0 125,199 66.7 26,946 65.1 7,480 70.2 5,052 64.9 11,438 63.0 706 70.3 2,270 60.6
1 31,063 16.5 7,382 17.8 1,707 16.0 1,390 17.8 3,338 18.4 160 15.9 787 21.0
2 17,967 9.6 4,003 9.7 882 8.3 761 9.8 1,901 10.5 81 8.1 378 10.1
3 13,556 7.2 3,031 7.3 587 5.5 586 7.5 1,489 8.2 57 5.7 312 8.3
Risk category
No PCa 187,785 100.0
Low risk 2,458 5.9 1,195 11.2 439 5.6 687 3.8 36 3.6 101 2.7
Intermediate risk 6,902 16.7 3,051 28.6 1,284 16.5 2,173 12.0 75 7.5 319 8.5
High risk 14,806 35.8 4,367 41.0 3,210 41.2 5,867 32.3 248 24.7 1,114 29.7
Regionally metastatic 5,955 14.4 1,200 11.3 1,386 17.8 2,682 14.8 158 15.7 529 14.1
Distant metastases 10,888 26.3 713 6.7 1,397 17.9 6,647 36.6 481 47.9 1,650 44.0
Missing data 353 0.9 130 1.2 73 0.9 110 0.6 6 0.6 34 0.9
Initial treatment
No PCa 187,785 100.0
ADT 31,149 75.3 5,266 49.4 6,075 78.0 15,565 85.7 827 82.4 3,416 91.2
Curative treatment 4,848 11.7 3,103 29.1 869 11.2 700 3.9 105 10.5 71 1.9
Active surveillance or
watchful waiting 5,365 13.0 2,287 21.5 845 10.8 1,901 10.5 72 7.2 260 6.9
No. of previous CVD events
(ICD-10: I00-I99)
0 161,064 85.8 35,487 85.8 9,191 86.3 6,676 85.7 15,491 85.3 891 88.7 3,238 86.4
1 8,527 4.5 1,923 4.6 427 4.0 407 5.2 880 4.8 38 3.8 171 4.6
2 11,569 6.2 2,487 6.0 668 6.3 424 5.4 1,142 6.3 42 4.2 211 5.6
3 6,625 3.5 1,465 3.5 370 3.5 282 3.6 653 3.6 33 3.3 127 3.4
Statin use before ADT
initiation
ADT before drug registry
start 50,808 27.1 12,246 29.6 1,235 11.6 3,895 50.0 5,321 29.3 165 16.4 1,630 43.5
No 98,780 52.6 20,899 50.5 6,565 61.6 2,804 36.0 9,297 51.2 630 62.7 1,603 42.8
Yes 38,197 20.3 8,217 19.9 2,856 26.8 1,090 14.0 3,548 19.5 209 20.8 514 13.7
Level of education
Low 89,824 47.8 20,200 48.8 4,290 40.3 4,068 52.2 9,173 50.5 413 41.1 2,256 60.2
Middle 62,552 33.3 13,880 33.6 3,938 37.0 2,517 32.3 6,003 33.0 352 35.1 1,070 28.6
High 31,549 16.8 6,719 16.2 2,337 21.9 1,088 14.0 2,707 14.9 227 22.6 360 9.6
Missing 3,860 2.1 563 1.4 91 0.9 116 1.5 283 1.6 12 1.2 61 1.6
Civil status
Married 122,236 65.1 27,385 66.2 7,506 70.4 5,209 66.9 11,736 64.6 640 63.7 2,294 61.2
Single 65,549 34.9 13,977 33.8 3,150 29.6 2,580 33.1 6,430 35.4 364 36.3 1,453 38.8
Abbreviations: ADT, androgen-deprivation therapy; CVD, cardiovascular disease; GnRH, gonadotropin-releasing hormone; ICD-10, International Classification of
Diseases, Tenth Revision; PCa, prostate cancer; PCBaSe, Prostate Cancer Database Sweden; SD, standard deviation.
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95%CI, 1.03 to 1.24). The risk of CVD remained high formenwith a
history of statin use in the GnRH group (HR for incident CVD, 1.20;
95%CI, 1.12 to 1.28; Table 3).
To assess the impact of ADTonCVD risk inmore detail, we also
calculated risk ratios of incident CVD in the 2 years before and after
initiation of ADT (Table 4). An evenmore increased risk of CVDwas
observed after initiation of GnRH agonists (HR for incident CVD
before initiation, 1.15; 95% CI, 1.10 to 1.20; HR after initiation, 1.28;
95% CI, 1.23 to 1.33). Men receiving AA were not at statistically
significantly increased risk of CVDbefore or after commencing ADT.
Those who underwent orchiectomy were at increased risk of CVD
after castration (HR for incident CVD before surgery, 0.96; 95% CI,
0.84 to 1.08; HR after surgery, 1.14; 95%CI, 1.02 to 1.28).
The association of ADT duration and number of previous CVD
events is shown in Figure 2.Men with two ormore CVD events, with
the latest occurringwithin a year before initiation of ADT, were at the
highest risk of CVD within the first 6 months of ADT (HRs for first
CVD event since start of ADT: AA HR, 1.60; 95% CI, 1.24 to 2.06;
GnRH agonists HR, 1.91; 95%CI, 1.66 to 2.20; and orchiectomyHR,
1.79; 95% CI, 1.16 to 2.76). This risk then decreased in the AA and
GnRH groups, whereas those who underwent orchiectomy were
still at high risk of CVDduringmonths 6 to 12 after castration (HR,
1.91; 95%CI, 1.31 to 2.78; Fig 2C).Minimal changes in risk of CVD
over ADT duration were observed in men with no history of CVD
and those who experienced an event 1 or more years before initia-
tion of ADT.
DISCUSSION
In this large observational study,we found a consistent increase in risk
of CVD for men with PCa on GnRH agonists compared with a
matchedPCa-free cohort.TheHRforCVDpeaked sharplyduring the
first 6monthsofADT.This associationwasparticularly strong among
menwithahistoryofmultipleCVDevents,with themost recent event
occurring within 1 year before ADT.
Results on the association between ADT and CVD have been
inconsistent in previous studies. Anobservational study conductedby
Martin-Merino et al12 found an adjusted odds ratio for acutemyocar-
dial infarctionof1.13 (95%CI,0.66 to1.94) inmenonGnRHagonists
compared with controls. Jespersen et al10 found a similar association
between ADT and CVD, but there was no detailed information on
type of ADT. In contrast, a recent meta-analysis of eight randomized
trials of 4,141menwithhigh-risknonmetastaticPCadidnotfind such
an association.24 Because data on history of CVD were not available,
the risk for men with pre-existing CVD could not be assessed.24,29,30
Thus, it currently cannot be excluded that there may be an increased
risk of CVD for men on ADT, and our data suggest that this risk is
higher for men with a history of CVD during the first 6 months of
treatment, as has previously been reported formenonGnRHagonists
versus antagonists.31
In our previous study, relative risks of CVD in men with PCa
were increased inmenwith PCa treatedwithADT comparedwith the
general Swedish male population.16 Moreover, the data suggested an
increased risk of CVD in men with a history of CVD before cancer
diagnosis.16 Byuseof data onage- and county-matchedPCa-freemen
and detailed information on ADT duration, the current study con-
firms these findings but also adds information to the temporal associ-
ation between ADT and CVD risk.
In the analysis of the association between ADT and CVD for
men who received primary ADT, the strength of the associations
increased slightly compared with the comparison cohort. Specula-
tively, high-risk PCa where treatment with ADT is indicated may
itself contribute to the increased risk of CVD, consistent with our
previous work where the risk of CVD was higher for men on ADT
than those on surveillance or curative treatment compared with
the general Swedish male population.16
Time on ADT also affected risk of CVD in our study. HRs for
CVDpeaked sharplyduring thefirst year ofADT formenonAA,men
on GnRH agonists, and men who underwent surgical orchiectomy.
This is consistent with previous data on the immediate risk of cardio-
vascular events in men with PCa on peroral estrogens.32-36 These
observations imply that the majority of cardiovascular events occur
shortly after the start of ADT, potentially because of an acute direct
drug effect, as previously proposed.37 Interestingly,menwith a strong
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Fig 2. Hazard ratios at selected time intervals since the start of androgen-deprivation therapy for first cardiovascular disease (CVD) event in men with differing
baseline CVD over duration of (A) gonadotropin-releasing hormone (GnRH) agonist, (B) antiandrogen (AA) therapy, and (C) surgical orchiectomy versus the
comparison cohort.
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history of CVDonAAwere at increased risk of CVDduring the first 6
months of pharmacologic ADT, suggesting that the stress of PCa
diagnosismayalso contribute to the early increase in riskofCVD.This
temporal pattern with an increase shortly after start of treatment also
has implications for the use of neoadjuvant and adjuvant ADT as well
as palliative ADT.
The mechanism by which ADT may increase risk of CVD is
currently poorly understood. A possible explanation for this
associationmaybe that the cardioprotectionprovidedby testosterone
is being interrupted by ADT.14-16,18 Alternatively, GnRH agonist–
mediated immune activation has also been linked to CVD via fibrous
cap disruption and plaque destabilization by activated circulating T
cellswith the capacity to express theGnRHreceptor.38-40 Risk ofCVD
was also comparatively high in the orchiectomy group, thus suggest-
ing an association between removal of testosterone from the circula-
tion and increased risk ofCVD. In further support of this, risk ofCVD
wasmarkedly lower in theAA group inwhich there is no reduction of
circulating testosterone. Indeed, decreased levels of androgens have
been shown to increase low-density lipoprotein, triglycerides, and
insulin, which are components of the metabolic syndrome, a strong
risk factor of CVD.41 Our data set does not contain any information
about these factors, but speculatively, thesemechanismsmay, in part,
play a role in the associations observed.
Finally, history of CVD was a contributing factor for the in-
creased risk of CVD after ADT. Men who experienced a CVD event
within1yearbefore the startofADTwereat thehighest riskduring the
first 6months of therapy comparedwith the comparison cohort. This
suggests that ADT rapidly increases risk of CVD inmenwith a recent
historyofCVD.Thus, itmaybe contemplated that someclinical effort
should be focused onmodification of CVD risk factors in these men.
Strengths of the study are its large size, complete follow-up,
and comparison to an age- and county-matched cohort free of
PCa. The National Prescribed Drug Register allowed us to accu-
rately anddirectly assess the filling of prescriptions for specific drug
therapies with detailed information on doses and iterations. We
also adjusted our multivariable regression models for proxies of
PCa progression, including TURP, palliative radiotherapy, and
nephrostomy. Limitations of our study include that we did not
have information about lifestyle factors, but all results were cor-
rected for CCI, which accounts for other morbidities.42,43 There
may still be residual confounders, such as confounding by indica-
tion of treatment, which could not be accounted for.
Our study suggests an increased risk of CVDwithin the first year
from starting GnRH agonist therapy or orchiectomy, especially in
men with history of a CVD event within 1 year before ADT. There
should be solid indication of use of ADT so that the perceived benefit
outweighs possible harm. This is particularly important inmenwith a
recent history of CVD.
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■ ■ ■
GLOSSARY TERMS
androgen-deprivation therapy (ADT): treatment that
suppresses or blocks the production or action of male hormones.
Cox proportional hazards regressionmodel: a statis-
tical model for regression analysis of censored survival data, ex-
amining the relationship of censored survival distribution to one
or more covariates. This model produces a baseline survival
curve, covariate coefficient estimates with their standard errors,
risk ratios, 95% CIs, and significance levels.
Gleason score: a pathologic description of prostate cancer
grade on the basis of the degree of abnormality in the glandular
architecture. Gleason patterns 3, 4, and 5 denote low, intermedi-
ate, and high levels of histologic abnormality and tumor aggres-
siveness, respectively. The score assigns primary and secondary
numbers on the basis of the most common and second most
common patterns identified.
hazard ratios: the ratio of the hazard rate in one group (for example,
a group of treated patients) to the hazard rate in another group (for ex-
ample, an untreated control group of patients). The hazard rate is the
probability of a specified event, such as death or cancer recurrence, oc-
curring during a short time interval. The hazard ratio, therefore, is a
measure of the relative probability of an event occurring at any given
point in time.
prostate-specific antigen (PSA): a protein produced by cells of
the prostate gland. The blood level of prostate-specific antigen (PSA) is
used as a tumor marker for men who may be suspected of having pros-
tate cancer. Most physicians consider 0 to 4.0 ng/mL to be the normal
range. Levels of 4 to 10 and 10 to 20 ng/mL are considered slightly and
moderately elevated, respectively. PSA levels have to be complemented
with other tests to make a firm diagnosis of prostate cancer.
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Appendix
Table A1. Event Counts and HRs for CVD in Men With PCa on GnRH Agonists Excluding Those on Combined Androgen Blockade Versus the Comparison
Cohort for All Men With PCa, Men Who Received ADT at Time of Diagnosis, Men With No History of CVD Before Starting ADT, and Men With a History
of Statin Use
CVD
Control Population
Patients on
GnRH
Agonists  Flare
Protection Control Population
Patients on GnRH
Agonists  Flare
Protection
No. % No. % HR 95% CI HR 95% CI
All men with PCa
All incident CVD 42,235 23.5 6,657 25.2 1.00 Reference 1.21 1.18 to 1.25
Ischemic heart disease 13,808 7.5 2,084 7.5 1.00 Reference 1.17 1.11 to 1.24
Arrhythmia 10,263 5.5 1,502 5.3 1.00 Reference 1.12 1.05 to 1.20
Heart failure 10,468 5.6 1,831 6.5 1.00 Reference 1.24 1.16 to 1.31
Stroke 13,916 7.5 2,081 7.4 1.00 Reference 1.12 1.06 to 1.18
All fatal CVD 21,654 11.5 3,316 11.6 1.00 Reference 1.06 1.01 to 1.11
Ischemic heart disease 9,720 5.2 1,606 5.6 1.00 Reference 1.15 1.08 to 1.23
Arrhythmia 1,601 0.9 225 0.8 1.00 Reference 1.00 0.84 to 1.19
Heart failure 2,386 1.3 368 1.3 1.00 Reference 0.94 0.82 to 1.08
Stroke 2,807 1.5 453 1.6 1.00 Reference 1.12 0.99 to 1.27
Men who received ADT at time of diagnosis
All incident CVD 42,235 23.5 5,488 20.8 1.00 Reference 1.19 1.15 to 1.23
Ischemic heart disease 13,808 7.5 1,749 6.3 1.00 Reference 1.17 1.10 to 1.25
Arrhythmia 10,263 5.5 1,235 4.4 1.00 Reference 1.10 1.02 to 1.19
Heart failure 10,468 5.6 1,567 5.5 1.00 Reference 1.22 1.14 to 1.31
Stroke 13,916 7.5 1,774 6.3 1.00 Reference 1.12 1.05 to 1.20
All fatal CVD 21,654 11.5 2,922 10.2 1.00 Reference 1.09 1.03 to 1.14
Ischemic heart disease 9,720 5.2 1,416 4.9 1.00 Reference 1.19 1.11 to 1.28
Arrhythmia 1,601 0.9 198 0.7 1.00 Reference 1.02 0.84 to 1.23
Heart failure 2,386 1.3 326 1.1 1.00 Reference 0.96 0.82 to 1.11
Stroke 2,807 1.5 398 1.4 1.00 Reference 1.14 1.00 to 1.31
Men with no history of CVD before starting ADT
All incident CVD 23,810 13.2 3,871 14.7 1.00 Reference 1.19 1.14 to 1.24
Ischemic heart disease 7,680 4.2 1,111 4.0 1.00 Reference 1.09 1.01 to 1.18
Arrhythmia 5,499 3.0 841 3.0 1.00 Reference 1.11 1.01 to 1.21
Heart failure 4,717 2.5 910 3.2 1.00 Reference 1.24 1.13 to 1.35
Stroke 8,674 4.7 1,308 4.7 1.00 Reference 1.09 1.01 to 1.17
All fatal CVD 11,379 6.1 1,832 6.4 1.00 Reference 1.07 1.01 to 1.14
Ischemic heart disease 4,944 2.6 829 2.9 1.00 Reference 1.14 1.04 to 1.25
Arrhythmia 846 0.5 125 0.4 1.00 Reference 1.01 0.80 to 1.27
Heart failure 1,264 0.7 221 0.8 1.00 Reference 0.98 0.82 to 1.18
Stroke 1,600 0.9 279 1.0 1.00 Reference 1.15 0.98 to 1.35
Men with a history of statin use
All incident CVD 9,594 5.3 1,390 5.3 1.00 Reference 1.20 1.12 to 1.28
Ischemic heart disease 3,529 1.9 535 1.9 1.00 Reference 1.30 1.17 to 1.44
Arrhythmia 2,229 1.2 259 0.9 1.00 Reference 1.01 0.88 to 1.18
Heart failure 2,369 1.3 371 1.3 1.00 Reference 1.18 1.04 to 1.35
Stroke 2,505 1.4 357 1.3 1.00 Reference 1.17 1.03 to 1.34
All fatal CVD 3,159 1.7 468 1.6 1.00 Reference 1.01 0.90 to 1.14
Ischemic heart disease 1,671 0.9 269 0.9 1.00 Reference 1.11 0.95 to 1.29
Arrhythmia 152 0.1 25 0.1 1.00 Reference 1.30 0.80 to 2.13
Heart failure 290 0.2 41 0.1 1.00 Reference 0.93 0.63 to 1.39
Stroke 376 0.2 57 0.2 1.00 Reference 0.98 0.69 to 1.38
Abbreviations: ADT, androgen-deprivation therapy; CVD, cardiovascular disease; GnRH, gonadotropin-releasing hormone; HR, hazard ratio; PCa, prostate cancer.
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